Ambrx Biopharma Cayman, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · E9 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | |
|---|---|---|
| Revenue | $7.4M | $7.5M |
| Operating income | −$76.4M | −$64.4M |
| Net income | −$78.0M | −$68.1M |
| Total assets | $147.0M | $229.0M |
| Total liabilities | $29.1M | $39.1M |
| Equity | $117.8M | $190.0M |
| EPS (diluted) | $-0.29 | $-0.48 |
| Shares out. | 270.5M | 270.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −1032.2%
- Net margin
- −1053.7%
- Return on equity
- −66.2%
- Return on assets
- −53.1%
- Return on capital (ROCE)
- −58.6%
- Liabilities / assets
- 19.8%
- Debt / equity
- 0.25×
- Book value / share
- $0.44
- Revenue growth (YoY)
- −0.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -2.41distress
- Accruals / assets
- −6.3%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Modified shareholder rights · Director / officer change · Other material eventOct 12, 2023
- Shareholder vote · Other material eventOct 10, 2023
- Director / officer changeOct 6, 2023
- Terminated a material agreement · Other material eventSep 25, 2023
- Entered a material agreement · Other material eventSep 15, 2023
- Director / officer changeSep 6, 2023
- Other material eventAug 25, 2023
- Results of operations · Other material eventJun 28, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.